IENTC Telecomunicaciones Selects VectorMax Corporation to Deliver IP Live Linear with SVOD to Support Growth in Mexico
16.6.2020 16:17:00 EEST | Business Wire | Press release
IENTC Telecomunicaciones, an internet and television service provider operating in the Mexican market, today announced it is launching VectorMax’s turn-key IPTV Platform as the software to support its new television product. Serving the market for more than 10 years, IENTC Telecomunicaciones’ new service augmenting its consumer offering reflects the growing shift from broadcast television to IP delivery of live linear TV.
This marks the first commercial deployment of an all software solution enabling operators to transition from broadcast to online delivery of live linear television without having to upgrade their network architecture. The software leverages $73M of R&D from teams out of MIT, IBM Labs, Bell Labs, DARPA and MPEG related projects to deliver multicast live linear as a turn-key, fully integrated, multicast software platform for cable operators, telcos, and high-speed access providers.
“Operators need to transition and support their entertainment experiences to remain relevant and competitive,” said Peter von Schlossberg, VectorMax’s President Global Product. “Our operators are searching for solutions to deliver a live linear consumer experience side-by-side with SVOD offerings from Netflix, Hulu, Amazon, Google, etc. VectorMax developed a unique software solution that capitalizes on existing infrastructure and networks to deliver high-quality live linear broadcast & other IP services.
“Transitioning to online delivery of live linear can be daunting, but VectorMax’s software platform allowed us to quickly see our consumer offering ingested and delivered in multicast by the VectorMax software. Our own branded Streaming Media Player apps on Amazon FireTV, Roku, Android STBs, Smart TVs and iOS were live within weeks. VectorMax’s ‘show-me’ sales strategy enabled us to easily determine they were the best fit to support the growing demands of our customers,” said Carlos Arguimbau, CEO of IENTC.
VectorMax’s ability to execute technological and marketing solutions with minimal disruption to our existing operations assured us that they were an important resource to navigate new market dynamics. The end product is a win-win for both IENTC and our customers,” said Arguimbau.
IENTC’s new +TV service is bolstered by a recent study from Hub Entertainment Research. The study found that the average number of television services accessed online per viewer in the US in the past 24 months reflected a rise of over 50%. That number is expected to trend globally. IENTC is also tracking the Hub findings reflecting pay-TV subscribers who have used an operator provided set-top box to watch streaming services tend to keep using it; 58% do so to access Netflix, 61% for Amazon, and 57% for Hulu.
“These findings are a key validation of providers’ efforts to aggregate streaming services as another way to create value in the set-top box and reduce cord-cutting”, said von Schlossberg.“VectorMax deployed our Platform in December which is now being expanded to a wider area of IENTC’s footprint in Mexico. Strategically, we are positioned to help cable companies and telecoms address this shift and to market new services as easily as flicking on a switch. The VectorMax Platform is slated for a roll-out to additional customers starting Q3 2020”.
About VectorMax Corporation
VectorMax’s pioneering of technologies that increase the efficiencies in delivering IP video over large scale, fully developed, and imperfect networks, solves the evolution of live linear broadcast television to on-network online delivery. The Company holds 102 worldwide patents grounded in software-based IP transport delivery technologies.
Supported with $73 million of R&D and twelve years of intensive research and development, conducted by a development team with MIT, IBM Labs, Bell Labs, DARPA & MPEG credentials, the Company delivers a complete end to end platform comprised of multiple modules designed to work together to deliver IPTV to large scale audiences over less than optimal networks within bandwidth constrained and limited infrastructure environments. The carrier requires no other third-party component to ingest, encode, manage and deliver the immersive experience that 2020 subscribers expect. Discover more at www.vectormax.com.
About IENTC Telecomunicaciones
IENTC Telecomunicaciones is a company with more than 10 years in the telecommunications industry located in the central zone of Mexico. With high-speed internet that is offered through its’ own fiber-optic network, providing best in class service and a customer experience that guarantees business is always connected. IENTC has the most advanced technology available in the market, which enables the offering of additional services such as Mobile phone, Virtual PBX, Smart Internet, and Television services among others. Discover more at ientc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005227/en/
Contact information
Bryen Aoyama
+1 (310) 403-2579
bryen@vectormax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom